Marinus Pharmaceuticals, Inc.
MRNSDelisted Feb 11, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001267813
Marinus Pharmaceuticals, Inc. was delisted on Feb 11, 2025; its insiders filed their last Form 4 on Feb 11, 2025; 53 institutions reported holding it in 13F filings for Q4 2024, worth $15.8M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 53
- Q4 2024, −22 vs. previous quarter
- 13F value
- $15.8M
- Reported value at the end of Q4 2024
- Superinvestors holding
- 0
- At the end of Q4 2024
Superinvestors holding MRNS, Q4 2024
No superinvestor reported holding MRNS at the end of Q4 2024.
Latest insider trades
Open-market purchases and sales by Marinus Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 11, 2025 (view filing) | Aug 14, 2024 | 181 daysLate | Braunstein ScottCHAIRMAN AND CEO | PPurchase | +5.93K | $1.10 | +$6.53K | +2.0%304.6K after | |
| Jan 23, 2025 (view filing) | Jan 21 | 2 days | Ezickson ElanDirector | SSale | −1.60K | $0.54 | −$864 | −12.8%10.9K after | 10b5-1 |
| Jan 23, 2025 (view filing) | Jan 21 | 2 days | Johnson MarvinDirector | SSale | −1.61K | $0.54 | −$869.4 | −11.4%12.5K after | 10b5-1 |
| Aug 7, 2024 (view filing) | Aug 5 | 2 days | Shafer ChristinaCHIEF COMMERCIAL OFFICER | SSale | −3.82K | $1.14 | −$4.35K | −5.4%67.4K after | |
| Aug 7, 2024 (view filing) | Aug 5 | 2 days | Pfanstiel StevenCFO AND COO | SSale | −4.66K | $1.13 | −$5.26K | −5.5%79.8K after | |
| Aug 7, 2024 (view filing) | Aug 5 | 2 days | Manning Martha ESVP, GEN. COUNSEL & CORP. SEC. | SSale | −3.62K | $1.13 | −$4.09K | −5.7%60.3K after | |
| Aug 7, 2024 (view filing) | Aug 5 | 2 days | Hulihan JosephCHIEF MEDICAL OFFICER | SSale | −4.83K | $1.13 | −$5.46K | −6.2%72.7K after | |
| Aug 7, 2024 (view filing) | Aug 5 | 2 days | Braunstein ScottCHAIRMAN AND CEO | SSale | −12.1K | $1.13 | −$13.7K | −3.9%298.7K after | |
| Feb 22, 2024 (view filing) | Feb 20 | 2 days | Shafer ChristinaCHIEF COMMERCIAL OFFICER | SSale | −2.15K | $9.56 | −$20.6K | −3.4%60.3K after | |
| Feb 22, 2024 (view filing) | Feb 20 | 2 days | Manning Martha ESVP, GEN. COUNSEL & CORP. SEC. | SSale | −1.89K | $9.57 | −$18.1K | −3.5%53.0K after |
Top 10 13F holders, Q4 2024
The largest institutional positions in Marinus Pharmaceuticals, Inc. at the end of Q4 2024; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Beryl Capital Management LLC | 4,227,460 | $2.26M | 0.51% | +4,227,460 | New |
| Morgan Stanley | 3,299,229 | $1.77M | 0.00% | +3,134,161+1,898.7% | Added |
| Oddo BHF Asset Management SAS | 2,700,000 | $1.44M | 0.07% | +2,700,000 | New |
| Bain Capital Life Sciences Investors, LLC | 2,693,380 | $1.44M | 0.17% | 00.0% | Unchanged |
| Standard Life Aberdeen plc | 2,658,527 | $1.42M | 0.00% | 00.0% | Unchanged |
| Vanguard Group Inc | 2,596,768 | $1.39M | 0.00% | −206,197−7.4% | Reduced |
| Woodline Partners LP | 2,335,681 | $1.25M | 0.01% | +1,071,410+84.7% | Added |
| Gsa Capital Partners LLP | 1,837,491 | $983.0K | 0.07% | +820,857+80.7% | Added |
| Tang Capital Management LLC | 1,641,945 | $878.6K | 0.06% | −3,058,055−65.1% | Reduced |
| BlackRock, Inc. | 883,675 | $472.9K | 0.00% | −975,534−52.5% | Reduced |
Holders of 5% or more of MRNS
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Marinus Pharmaceuticals, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Suvretta Capital Management, LLC | 13G | 5.50%3.02M shares | +1.70 ppfrom 3.80% | Aug 20, 20215 filings | Feb 11, 2025 | SEC |